FDA Approval Alert: The Need-to-Know | Tafasitamab Plus Lenalidomide/RItuximab in R/R Follicular Lymphoma

In June 2025, the FDA approved tafasitamab-cxix in combination with lenalidomide and rituximab as a treatment for patients with relapsed or refractory follicular lymphoma.

Tafasitamab combined with lenalidomide and rituximab demonstrated a median OS of 22.4 months vs 13.9 months with placebo in patients with follicular lymphoma.
FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma
Article
Jun 18, 2025 7:36 PM
Tafasitamab combined with lenalidomide and rituximab demonstrated a median OS of 22.4 months vs 13.9 months with placebo in patients with follicular lymphoma.